ISB-1302 is under clinical development by Ichnos Sciences and currently in Phase II for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Phase II drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ISB-1302’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ISB-1302 overview

ISB-1302 (GBR-1302) is under development for the treatment of HER2 positive breast cancer. The drug candidate is a new biological entity, and it is administered  by the intravenous and subcutaneous route. It is a bi-specific monoclonal antibody which acts by targeting HER2 and CD3. The development of the drug candidate is based on BEAT (Bi-specific Engagement by Antibodies based on the T cell receptor) antibody technology platform. It was also under development for the treatment of gastric cancer and ovarian cancer.

Ichnos Sciences overview

Ichnos Sciences is a bio pharmaceutical manufacturing company. The company is engaged in developing therapies for treating oncology and autoimmune disease. It’s technology portfolio includes BEAT (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform which uses a novel method for engineering bispecific antibodies that may treat cancers and ISB 830 is designed to block the key immune system activation factor to treat a variety of illnesses and provides an entirely novel method of action for the treatment of autoimmune disease. Ichnos Sciences is headquartered in New York, the US.

For a complete picture of ISB-1302’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.